Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma

Kwok, Philip Chong-hei; Lam, Ting Wa; Lam, Polly Woon-Yee; Tang, Kwok Wai; Chan, Susan Chi-hum; Hwang, J.S.T.; Cheung, Moon‐Tong; Tang, Donald Lap‐Chiu; Chung, T K; Chia, Nam-Hung; Wong, Wong Kan; Chan, Michael C. W.; Lo, Hong Yuen; Lam, Wai Ming

doi:10.1046/j.1440-1746.2003.03015.x

Cited by 23 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor dormancy, observed clinically, is generally thought to reflect the existence of residual tumor cells that fail to respond to a conventional treatment regimen (15)(16)(17)(18). Residual tumor cells may be kept in check by various mechanisms, including the host immune system, tumor cell microenvironment, and/or angiogenic or autocrine growth factor capability (19)(20)(21)(22)(23).…”

Section: Tumor Dormancy and Cancer Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy

Shachaf

Felsher

2005

Cancer Research

View full text Add to dashboard Cite

Upon MYC inactivation, tumors undergo proliferative arrest, cellular differentiation, apoptosis and in some cases, permanently revoke tumorigenesis. In liver tumor cells, we recently showed that MYC inactivation uncovers stem cell properties and triggers differentiation, but in this case, their neoplastic properties are restorable by MYC reactivation. Thus, whereas oncogene inactivation can push cancer to the brink of normalcy, some cells retain the latent capacity to turn cancerous again, arguing that they may exist in a state of tumor dormancy. (Cancer Res 2005; 65(11): 4471-4)

show abstract

Section: Tumor Dormancy and Cancer Stem Cellsmentioning

confidence: 99%

“…Treatment of many types of cancers, including breast cancer, lymphoma, leukemia, and sarcomas, can be associated with long-term regression of tumors, only to be followed by relapse at a much later time (15)(16)(17)(18). The specific type of cancer can often predict the outcome of treatment.…”

Section: Clinical and Therapeutic Implications Of Tumor Dormancymentioning

confidence: 99%

Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy

Shachaf

Felsher

2005

Cancer Research

View full text Add to dashboard Cite

show abstract

“…In another study, postoperative intra-arterial injection of iodine131 labeled lipiodol (131I-Lip) was found to decrease the HCC recurrence rate in patients after hepatectomy, improving the 1-, 2-, and 3-year survival rates when compared with the survival rates in the control group receiving no 131I-Lip treatment [34] . The adjuvant chemotherapy was not effective in preventing the postoperative recurrence [35] . The mechanisms of the anticancer effect of P 32 -GMS have been discussed.…”

Section: Discussionmentioning

confidence: 93%

Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy

Wang¹,

Yin²,

Yu³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…In a recent prospective randomized controlled trial, Kwok et al demonstrated that the positive benefits of using TACE as an adjuvant treatment are unclear. 7 In contrast, Ren et al demonstrated that postoperative adjuvant TACE can prolong the survival of patients with risk factors for residual tumour, but could not prolong the survival of patients without risk factors for residual tumour. 8 In a recent meta-analysis the authors suggested that the use of postoperative transarterial chemotherapy with or without embolization may improve survival.…”

Section: Discussionmentioning

confidence: 96%

Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience

Li¹,

Cheung²

2008

Surgical Practice

View full text Add to dashboard Cite

Aim:The aim of the present paper was to determine the pattern of recurrence and prediction for survival after primary curative surgical resection of hepatocellular carcinoma (HCC). Methods: This was a retrospective single institutional review. During 2002During -2005 patients had hepatectomies at Queen Elizabeth Hospital The total number of patients with primary curative liver resection was 113, and 103 patients were included in this survival analysis. Results: The recurrence rate was 49/103 (47.6%). The operative mortality rate was 4/113 (3.5%). The median time for recurrence was 13.5 months (range, 1-60 months). The mean follow-up period was 26.03 months (range, 1-60 months).Overall survival was 90%, 72% and 50%, at 1, 3 and 5 years, respectively, and diseasefree survival was 55%, 48% and 42%, at 1, 3 and 5 years, respectively. On univariate analysis, tumour > 10 cm, close (Յ 1 mm)/focally involved/involved resection margin, operative blood loss > 2500 mL, presence of satellite tumour nodules, vascular invasion and poor tumour differentiation were found to be associated with recurrence. On multivariate analysis presence of multiple satellite tumour nodules and presence of vascular invasion predicted poor disease-free survival whereas vascular invasion was the only predictor for overall survival. Conclusion: Patients who had curative surgical resection for HCC should be considered for adjuvant therapy when these high-risk factors are present.

show abstract

Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma

Abstract: There is no significant difference in the survival rates between the two groups. Adjuvant chemotherapy may not be useful.

Cited by 23 publications

References 15 publications

Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy

Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy

Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy

Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience

Contact Info

Product

Resources

About